Status:
UNKNOWN
Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism
Lead Sponsor:
Gyeongsang National University Hospital
Conditions:
Coronary Artery Stenosis
Maximal Platelet Aggregation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study was to determine the impact of adjunctive cilostazol on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 allele.
Detailed Description
The additional platelet inhibition with clopidogrel, a thienopyridine inhibitor of the platelet P2Y12 adenosine diphosphate (ADP) receptor, has reduced the risk of ischemic events after coronary stent...
Eligibility Criteria
Inclusion
- The patient must be at least 18 years of age
- Significant coronary artery stenosis (\> 70% by visual estimate)
- Elective coronary stent implantation
Exclusion
- Acute myocardial infarction
- Hemodynamic instability active bleeding and bleeding diatheses
- Oral anticoagulation therapy with warfarin,use of peri-procedural glycoprotein IIb/IIIa inhibitors
- Contraindication to antiplatelet therapy
- Left ventricular ejection fraction \< 30%
- Leukocyte count \< 3,000/mm3, platelet count \< 100,000/mm3
- AST or ALT ≥ 3 times upper normal
- Serum creatinine level ≥ 2.5 mg/dL
- stroke within 3 months
- Noncardiac disease with a life expectancy \< 1 year
- Inability to follow the protocol
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00891670
Start Date
May 1 2009
End Date
July 1 2009
Last Update
May 1 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gyeong-Sang National University Hospital
Jinju, Gyeong-Nam, South Korea, 660-702